Skip to main content
Caplight Logo









Inventprise

Inventprise

Private
Redmond, WashingtonHealthcare & Life Scienceshttps://inventprise.com/

Last Round

Series A

May 4, 2023

Total Funding Raised

$115.83M

Company Overview

Inventprise is a biotechnology company that develops high-valency vaccines for infectious diseases using proprietary linker conjugation technology and automated manufacturing processes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

pneumococcal vaccineconjugate vaccinebiotechnologyclinical trialsvaccine developmentbiopharmavaxclinical-stage biotechglobal healthvaccine candidatephilanthropic fundingimmunization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inventprise Comparables

Compare Inventprise with similar companies based on industry and business-model similarity.

Inventprise comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GSK plc
80%
GPN Vaccines
79%
Vaxcyte
79%

Inventprise Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 4, 2023
GrantApr 7, 2022
VC RoundNov 10, 2021
GrantMar 1, 2021
DebtJun 3, 2020
Grant
Mar 1, 2020

Key People

Founding team and executive leadership

Yves Leurquin

Chief Executive Officer

Executive Team

Jeff Wilson

Chief Financial Officer

Executive Team

Pradip Ghate

Chief Operating Officer

Executive Team

Inventprise Investors

Notable investors and investment history

Inventprise investors
InvestorRounds
Gates FoundationGrant
The Bill & Melinda Gates Foundation TrustGrant, Series A, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2025

    76 employees impacted according to state filing.

  • May 15, 2025

    Developing an RSV vaccine as a proof of concept.

Inventprise Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Inventprise Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inventprise's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedmond, Washington
Employee Range101
Year Founded2012
Last FundingMay 4, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?